Advantages of NMNH
NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity（up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
Advantages of NADH
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
Advantages of NAD
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
Advantages of MNM
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity（up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
We Have The Best Solutions for Your Business
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
NADH powder manufacturing method
The main methods of NADH powder preparation include extraction, fermentation, fortification, biosynthesis and organic matter synthesis. Compared with other preparations, the whole enzyme become the mainstream method owing to the advantages of pollution free, high level of purity and stability.
NADH powder efficacy in health
Improved energy levels
Not only does NADH act as an important coenzyme in aerobic respiration, the [H] of NADH also carries a large amount of energy. Studies have demonstrated that extracellular use of NADH promotes increased intracellular ATP levels, suggesting that NADH penetrates cell membranes and elevates intracellular energy levels. On a macro level, exogenous supplementation of NADH helps to restore energy and enhance appetite. The increase in energy levels in the brain also helps to improve mental performance and sleep quality. NADH has been used overseas to improve chronic fatigue syndrome, increase exercise endurance, jet lag and other areas.
Cellular protection
NADH is a strong antioxidant that naturally occurs in cells and reacts with free radicals to inhibit lipid peroxidation, protecting mitochondrial membranes and mitochondrial function. It has been found that NADH can reduce oxidative stress in cells caused by various factors such as radiation, drugs, toxic substances, strenuous exercise and ischemia, thus protecting vascular endothelial cells, hepatocytes, cardiomyocytes, fibroblasts and neurons. Therefore, injectable or oral NADH is used clinically to improve cardiovascular and cerebrovascular diseases, and as an adjunct to cancer radiotherapy. Topical NADH has been shown to be effective in the treatment of rosacea and contact dermatitis.
Promotion of neurotransmitter production
Studies have shown that NADH significantly promotes the production of the neurotransmitter dopamine, a chemical signal that is essential for short-term memory, involuntary movements, muscle tone and spontaneous physical responses. It also mediates the release of growth hormone and determines muscle movement. Without sufficient dopamine, muscles become stiff. Parkinson's disease, for example, is caused in part by a disruption of dopamine synthesis in brain cells. Preliminary clinical data suggest that NADH can help improve the symptoms of Parkinson's disease [9]. NADH also promotes the biosynthesis of norepinephrine and serotonin, showing good potential for use in the relief of depression and Alzheimer's disease.
BONTAC NADH product features and advantages
1、“Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder
2、Exclusive“Bonpure” seven-step purification technology, high purity（up to 99%) and stability of production of NADH powder
3、Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMN powder
4、Provide one-stop product solution customization service
User Reviews
What users say about BONTAC
Frequently Asked Question
Do you have any question?
NADH is synthesized by the body and thus is not an essential nutrient. It does require the essential nutrient nicotinamide for its synthesis, and its role in energy production is certainly an essential one. In addition to its role in the mitochondrial electron transport chain, NADH is produced in the cytosol. The mitochondrial membrane is impermeable to NADH, and this permeability barrier effectively separates the cytoplasmic from the mitochondrial NADH pools. However, cytoplasmic NADH can be used for biologic energy production. This occurs when the malate-aspartate shuttle introduces reducing equivalents from NADH in the cytosol to the electron transport chain of the mitochondria. This shuttle mainly occurs in the liver and heart.
The action of supplemental NADH is unclear. Oral NADH supplementation has been used to combat simple fatigue as well as such mysterious and energy-sapping disorders as chronic fatigue syndrome and fibromyalgia. Researchers are also studying the value of NADH supplements for improving mental function in people with Alzheimer's disease, and minimizing physical disability and relieving depression in people with Parkinson's disease. Some healthy individuals also take NADH supplements orally to improve concentration and memory capacity, as well as to increase athletic endurance. However, to date there have been no published studies to indicate that using NADH is in any way effective or safe for these purposes
First, inspect the factory. After some screening, NADH companies that directly face consumers pay more attention to brand building. Therefore, for a good brand, quality is the most important thing, and the first thing to control the quality of raw materials is to inspect the factory. Bontac company actually manufacturing NADH powder of high quality with the caterias of SGS. Secondly, the purity is tested. Purity is one of the most important parameters of NMN powder. If high purity NMN cannot be guaranteed, the remaining substances are likely to exceed the relevant standards. As the attached certificates demonstrates that the NADH powder produced by Bontac reach the purity of 99%. Finally, a professional test spectrum is needed to prove it. Common methods for determining the structure of an organic compound include Nuclear Magnetic Resonance Spectroscopy (NMR) and high-resolution mass spectrometry (HRMS). Usually through the analysis of these two spectra, the structure of the compound can be preliminarily determined.
Our updates and blog posts
NR as a Driver of Macrophage Migration to Boost Chronic Wound Healing
Introduction Wound healing is a sophisticated process responding to tissue damage, which is associated with numbers of interaction of various cell types, cytokines, growth factors, and other molecules. Strikingly, increasing the nicotinamide adenine dinucleotide (NAD) pool by nicotinamide riboside (NR) can accelerate wound healing and macrophage migration, which is partially achieved through PGE2 synthesis and signaling as well as the function of the NAD+-dependent sirtuin, SIRT3. Regulatory effects of NR on the expression of M1 macrophage markers in human MDMs. NR could modulate the expression levels of canonical M1 (inflammatory phenotype) and M2 (reparative phenotype) cell surface markers during macrophage polarization. With a great detail, a significant downregulation in CD64 and a obvious upregulation of CD197/CCR7 are viewed in the polarized M1 cells incubated with NR. Furthermore, NR increases CD197/CCR7-mediated M1 macrophage migration. The significance of chemotaxis mediator PGE2 in NR-regulated macrophage migration NR-mediated upregulation of macrophage migration through CCL19/CCR7 is dependent on the synthesis of PGE2, an inflammatory lipid mediator in the eicosanoid family. Concretely, NR administration increases the PGE2 level in cultured human monocytes, MDMs, and human serum. In addition, NR-mediated increases in CCR7 expression and CCL19-induced migration are attenuated by PGE2 synthesis blockers. NR/SIRT3/migration axis in human M1 MDMs NR facilitates collective cell migration at a SIRT3-dependent manner in human M1 MDMs during wound healing. Simply put, the degree of wound healing is compared on Day 0 and Day 2 in vehicle- or NR-treated human M1 MDMs. It is found that NR increases the relative degree of migration (relative wound healing) and the rate of wound confluence in the presence of CCL19. Besides, the relative degree of wound density (migration) is blunted by SIRT3 knockdown, while being enhanced by SIRT3 overexpression. Application prospect of NR in wound healing Chronic diabetes is often accompanied with poor wound healing. For instance, diabetic foot ulcers, one of the chief cause of amputations, affect 15% of people with diabetes. Given that NR can drive the macrophage migration to boost chronic wound healing, it may have a broad application prospect in treating the wounds including but not limited to diabetic patients. Conclusion In human macrophages, NR induces surface expression of the chemotaxis CD197/CCR7 receptor and levels of its lipid mediator PGE2 via upregulation of cyclooxygenase 2 and functionally increases macrophage migration and wound healing in a SIRT3-dependent manner. Reference Wu J, Bley M, Steans RS, et al. Nicotinamide Riboside Augments Human Macrophage Migration via SIRT3-Mediated Prostaglandin E2 Signaling. Cells. 2024;13(5):455. Published 2024 Mar 5. doi:10.3390/cells13050455 BONTAC NR BONTAC is one of the few suppliers in China that can launch mass production of raw materials for NR, with self-owned factory and professional R&D team. Up till now, there are 173 BONTAC patents. BONTAC provides one-stop service for customized products. Both malate and chloride salt forms of NR are available. By dirt of unique Bonpure seven-step purification technology and Bonzyme Whole-enzymatic method, the product content and conversion rate can be maintained in a higher level. The purity of BONTAC NR can reach above 97%. Our products are subjected to strict third-party self-inspection, which are worth of trustworthy. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.
NR as a Promising Therapeutic Candidate for Alpers' Disease
Introduction Alpers' disease is both a neurodegenerative disorder and a metabolic disorder, which is tightly linked to mitochondrial dysfunction and mutations in the catalytic subunit of polymerase gamma (POLG) gene. Noteworthily, supplementation of NAD precursor, nicotinamide riboside (NR), is evidenced to explicitly ameliorate mitochondrial defects in cortical organoids of patients with Alpers' disease. About Alpers’ disease Alpers’ disease is an autosomal recessive disorder, which is often accompanied with cortical neuronal loss as well as depletion of mitochondrial DNA (mtDNA) and complex I (CI). The disease occurs in about 1 in 100,000 newborns. Most individuals with Alpers’ disease show no symptoms at birth. Diagnosis is generally established by determining the POLG gene. Once onset (usually between first and third years of life), patients may present the symptoms such as progressive encephalopathy, epilepsy, myoclonus, and myasthenia gravis. Currently, there is no effective method to cure this disease. Establishment of Alpers' disease model in vitro Induced pluripotent stem cells (iPSCs) are generated from Alpers' patient carrying the compound heterozygous mutations of A467T (c.1399G>A) and P589L (c.1766C>T), followed by differentiation into cortical organoids and neural stem cells (NSCs). Alpers's iPSCs exhibit mild mitochondrial alterations, including an elevated L-lactate level and a depletion of CI. Alpers' NSCs manifest profound mtDNA depletion and mitochondrial dysfunction. Alpers' cortical organoids demonstrate cortical neuronal loss and astrocyte accumulation. The role of NR in Alpers' cortical organoids Long-term treatment with NR partially ameliorates the neurodegenerative alterations observed in Alpers' cortical organoids. Specifically, supplementation of NR effectively counteracts neuronal loss, glial enrichment, and mitochondrial damage observed in cortical organoids of patients with Alpers' disease. Reversal of the dysregulated pathways in Alpers' patient organoids post NR treatment NR treatment offsets the downregulation of mitochondrial and synaptogenesis-related pathways, as well as upregulation of pathways associated with astrocyte/glial cells and neuroinflammation are obviously activated in Alpers' cortical organoids. Conclusion Replenishment of NR to increase NAD level can rescue mitochondrial defects and neuronal loss in iPSC-derived cortical organoid of Alpers’ disease, with relatively high safety and bioavailability, showing great promise as a therapeutic candidate for this intractable disorder. Reference Hong Y, Zhang Z, Yangzom T, et al. The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC derived Cortical Organoid of Alpers' Disease. Int J Biol Sci. 2024;20(4):1194-1217. Published 2024 Jan 25. doi:10.7150/ijbs.91624 BONTAC NR BONTAC is one of the few suppliers in China that can launch mass production of raw materials for NR, with self-owned factory and professional R&D team. Up till now, there are 173 BONTAC patents. BONTAC provides one-stop service for customized products. Both malate and chloride salt forms of NR are available. By dirt of unique Bonpure seven-step purification technology and Bonzyme Whole-enzymatic method, the product content and conversion rate can be maintained in a higher level. The purity of BONTAC NR can reach above 97%. Our products are subjected to strict third-party self-inspection, which are worth of trustworthy. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The opinions expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.
Improvement of Rheumatoid Arthritis Via MSCs-Exo in Combination With Rh2
Introduction In light of a statistics report by World Health Organization (WHO), there are 18 million people suffering from rheumatoid arthritis (RA) worldwide in 2019, where the prevalence of female is 2.5 times that of male. This disorder greatly affects the life quality of patients and even causes disability in severe case. Noteworthily, mesenchymal stem cell-derived exosome (MSCs-exo) in combination with ginsenoside Rh2 has been unveiled to be effective in alleviating RA symptoms, holding a great promise as an adjuvant drug for RA. About RA RA represents a chronic autoimmune disease generally occurring in middle age, which is chiefly featured by vascular proliferation, synovium inflammation and the stiffness/swelling/deformation/pain of one or more joints. At present, the treatment of RA relies on corticosteroids, nonsteroidal anti-inflammatory drugs, synthetic disease-modifying anti-rheumatic drugs, and biological agents. Yet, long-term use of these drugs may be accompanied with various adverse effects such as infection, liver damage, gastrointestinal damage, and heart failure. MSCs vs. MSCs-exo MSCs, with multiple differentiation potential, can reduce joint inflammation in RA. Nevertheless, there are potential risks such as immunogenicity, heterogeneity of different batches of cells, tumorigenicity, and ethical issues, limiting the application of MSCs. MSCs-exo is small extracellular vesicle secreted by MSCs, whose diameter ranges from 30 to 150 nanometers. It can carry biologically active substances such as nucleic acids and small molecules, fulfilling the function of MSCs. Relative to MSCs, MSCs-exo has low immunogenicity and has no risk of tumor formation and ethical constraints. Research protocol A collagen-induced arthritis (CIA) model is constructed in rats, followed by the treatment of phosphate-buffered saline or single/combined therapy of MSCs-exo and ginsenoside Rh2. The rat fences are collected for 16 rRNA amplification sequencing and untargeted metabolomics analysis. Significant efficacy of MSCs-exo combined with ginsenoside Rh2 in RA The combined therapy of MSCs-exo and ginsenoside Rh2, to a large extent, ameliorates RA symptoms in CIA model rats, as manifested by the reduction of joint swelling as well as significant decline in arthritis score and paw thickness. Meanwhile, the histopathological changes in CIA model rats are apparently improved. Rh2 enhances the ability of MSC-exo to suppress the expression of inflammatory factors in synovium and cartilage of CIA model rats, as evidenced by the downregulation of TNF-α, IL-1β and IL-6 as well as upregulation of IL-10 in exo+Rh2 group. Besides, bone erosion in the ankle joints of CIA rats is improved, as attested by the obvious increases in BMD and Tb.Th, as well as prominent decreases in BS/BV and Tb.Sp in exo+Rh2 group. Essential role of gut-joint axis in RA Gut microbiota and metabolites have been deemed to be critical in developing RA. Strikingly, MSCs-exo and Rh2 can significantly ameliorate the disturbed gut microbiota in CIA model rats. The regulation of Candidatus_Saccharibacteria and Clostridium_XlVb may be the most pivotal. Concretely, Candidatus_Saccharibacteria modulates the metabolic pathway of vitamin digestion and absorption by pantothenic acid and vitamin D3 alterations. As for Clostridium_XlVb, it regulates 16(R)-HETE alterations in the arachidonic acid metabolic pathway. Conclusion MSCs-exo and Rh2 act synergistically to ameliorate RA by modulating the gut microbiota and metabolites, especially the reshaping of Candidatus_Saccharibacteria and Clostridium_XlVb abundance. Reference Zhou Z, Li Y, Wu S, et al. Host-microbiota interactions in collagen-induced arthritis rats treated with human umbilical cord mesenchymal stem cell exosome and ginsenoside Rh2. Biomed Pharmacother. Published online April 2, 2024. doi:10.1016/j.biopha.2024.116515 BONTAC Ginsenosides BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team. BONTAC has rich R&D experience and advanced technology in the biosynthesis of rare ginsenosides Rh2/Rg3, with pure raw materials, higher conversion rate and higher content (up to 99%). Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be responsible or liable in any way for any claims, damages, losses, expenses, or costs arising directly or indirectly from your reliance on the information and material on this website.